GluCl.Cre ON enables selective inhibition of molecularly defined pain circuits.

"Conflict of interest statement D.L.B. has acted as a consultant on behalf of Oxford Innovation for Abide, Amgen, G Mitsubishi, Tanabe, GSK, TEVA, Biogen, Lilly, Orion, and Theranexus."

"Authors will make available data used in this article to any researcher for purposes of reproducing the results or replicating the procedure. Data transfer requests should be made to the corresponding author(s). The author(s) thank John Wood for providing the Nav1.8Cre mouse line. This research was funded in whole, or in part, by the Wellcome Trust (102645/Z/13/Z, 202747/Z/16/Z, and 109116/Z/15/Z). D.L.B. is a Wellcome senior investigator (223149/Z/21/Z). D.L.B. and S.J.M. acknowledge funding from the UK Medical Research Council (grant ref. MR/T020113/1). G.A.W. acknowledges funding from the UK Medical Research Council (grant ref. MR/T01072X/1). H.H. acknowledges the funding from China Scholarship Council (CSC)."